查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092157

藥物研發服務市場－2026-2032年全球市場預測

Drug Discovery Services Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物研發服務市場將成長至 319 億美元，複合年成長率為 10.59%。

主要市場統計數據
基準年 2025 157.6億美元
預計年份：2026年 173.1億美元
預測年份 2032 319億美元
複合年成長率 (%) 10.59%

藥物發現服務在製藥、生物技術、學術和公共衛生機構的新療法候選藥物的識別、檢驗、最佳化和開發中發揮著日益重要的作用。這些服務涵蓋標靶識別、檢測方法開發、高通量篩檢、先導化合物最佳化、藥物化學、結構生物學、體外和體內藥理學、ADME（吸收、分佈、代謝和排泄）、毒理學、生物標記發現以及早期轉化研究。需求的促進因素包括降低研發失敗率、提高可重複性、縮短研發週期以及充分利用生物製劑、胜肽、寡核苷酸、細胞和基因療法、放射性藥物和靶向蛋白水解藥物等複雜藥物領域的專業知識。從科學角度來看，數十年的證據支持這一領域，表明早期失敗通常是由標靶檢驗不足、藥物動力學性質不佳、出現毒性徵兆以及缺乏轉化相關性造成的。因此，贊助商優先考慮整合生物學、化學、計算建模、疾病相關檢測和品管數據產生的一體化藥物研發服務。經營團隊的首要任務不再只是外包單一任務，而是建立一個強大的藥物研發生態系統，以改善決策、縮短實驗學習週期，並支援從藥物發現到臨床前開發的更穩健的過渡。

藥物研發服務產業的變革性變化

藥物研發服務的格局正在經歷一場變革，其驅動力包括科學的複雜性、監管要求、數位化以及研發網路的全球化。其中一個關鍵轉變是從線性外包到整合式藥物研發夥伴關係的轉變，在這種模式下，跨領域團隊就治療假設、標靶生物學、化學策略和轉換終點展開合作。另一個夥伴關係是擴大使用疾病相關模型，包括患者來源細胞、類器官、先進的共培養系統和人源化模型，以加強臨床試驗前的生物驗證。精準醫療也正在重塑藥物研發工作流程，將基因組學、蛋白質組學、代謝體學、表現型數據和生物標記策略與早期患者細分相結合。同時，監管科學領域要求提供更可靠的證據包，以證明藥物的安全性、作用機制、資料完整性和模型有效性。自動化、實驗室資訊管理系統、電子筆記本和標準化資料管道正在提高藥物研發的可重複性和可審計性。這些變化正在創造一個更以證據主導的服務環境，在這個環境中，雖然速度仍然很重要，但決策品質、可追溯性和轉化有效性變得越來越重要。

人工智慧對藥物發現服務的累積影響

人工智慧正透過改進機構探索化學和生物學空間、確定標靶累積、設計分子、解讀體學數據以及規劃實驗的方式，對整體藥物研發服務產生累積性影響。人工智慧驅動的方法正被應用於標靶辨識、蛋白質結構預測、虛擬篩檢、從頭分子設計、合成路線規劃、基於影像的表現型篩檢、毒性預測和病患分層。儘管同儕審查的結構預測和基於機器學習的分子建模方面的進展已證明其在假設生成方面的實用價值，但實驗室檢驗仍然至關重要，因為計算預測可能受到資料集偏差、生物學見解不完整以及疾病間可遷移性低等因素的限制。因此，實施人工智慧最有效的方式並非取代實驗藥物研發，而是採用封閉回路型模型：演算法提出提案，實驗室檢驗，並根據驗證數據改進後續預測。對於服務供應商和贊助商而言，人工智慧的策略價值在於減少無效實驗、識別細微模式、改進化合物優先排序以及實現更系統化的投資組合決策。隨著人工智慧融入藥物研發過程，資料管治、模型透明度、安全的資料共用和嚴格的檢驗正成為關鍵的差異化因素。

全球藥物研發服務的關鍵區域洞察

亞太地區正透過生物技術叢集的擴張、政府支持的生物醫學創新、高科研產出以及主要經濟體中具有成本競爭力的研究基礎設施，不斷加強其在藥物研發服務領域的角色。該地區受益於大規模的患者群體、不斷擴展的臨床和轉化研究能力，以及對基因組學、生物製劑和精準醫學領域日益成長的投資。北美仍然是先進藥物研發科學的領先中心，這得益於成熟的製藥和生物技術生態系統、強大的學術研究、創業投資資金、先進的實驗室基礎設施以及優先考慮數據品質和安全的完善監管流程。拉丁美洲正透過基於生物多樣性的研究、不斷提升的臨床研究能力以及不斷擴大的產學研合作（尤其是在感染疾病、腫瘤學和代謝性疾病領域）提升其重要性。歐洲繼續重視高品質的生物醫學研究、嚴格的監管、跨境科學合作以及公私合營的創新框架，並在轉化醫學、生物製藥、罕見疾病和先進療法方面擁有顯著優勢。在中東，各國正增加對生物醫學研究能力、基因組研究計畫、專業醫療基礎設施和創新區的投資，以支持生命科學領域的長期多元化發展。在不斷擴展的研究網路和國際合作的支持下，非洲在感染疾病研究、基因組監測、人群健康調查以及本地化療法創新方面發揮著日益重要的作用。在全部區域，藥物研發服務的發展都受到科學專業知識、符合倫理的研究實踐、強大的資料基礎設施以及對區域特定疾病的深入了解等因素的影響。

來自影響藥物發現服務的關鍵群體的見解

東協正崛起為生命科學領域的合作區域，這得益於其不斷擴展的生物醫學研究能力、日益加強的監管合作以及對感染疾病、代謝性疾病、腫瘤學和熱帶醫學研究日益成長的興趣。海灣合作理事會（GCC）成員國作為其更廣泛的經濟多元化策略的一部分，正優先發展醫療衛生、基因組醫學、生物技術投資和研究基礎設施，從而為精準醫療和區域特定疾病負擔相關的藥物研發夥伴關係創造了機會。歐盟透過其協調一致的法規結構、跨國研究計畫、強大的學術網路以及對資料保護、倫理和轉化科學的堅定承諾，為藥物研發服務提供了高度結構化的環境。金磚國家憑藉其規模、科研人才、製造網路、多樣化的疾病人群以及不斷成長的公共和私人生物技術投資，在從藥物研發到下游開發整合的各個環節發揮著至關重要的作用。七國集團（G7）國家憑藉其先進的研究機構、成熟的知識產權框架、高標準的監管以及在生技藥品、電腦輔助藥物研發、高級分析和複雜療法方面積累的專業知識，繼續發揮著重要的影響力。雖然北約成員國並非生命科學領域的統一組織，但它們高度重視健全的生物醫學研究體系和可靠的數據基礎設施，並涵蓋許多與國防相關的經濟領域，例如醫療保健、生物防禦、感染疾病控制和穩健的藥品供應鏈。這些組織透過政策協調、研究經費投入、跨國合作、監管預期以及建構安全且以創新為導向的生態系統，共同塑造藥物研發服務。

主要國家藥物研發服務的發展趨勢

美國是領先的藥物研發中心，擁有緊密相連的生物技術公司網路、大學附屬醫療中心、一流實驗室、創業投資資金以及涵蓋小分子藥物、生技藥品和先進療法的監管經驗。加拿大依托合作的公共研究體系，在學術研究、生技藥品、免疫學、神經科學和轉化醫學領域展現強大的實力。墨西哥正透過與製藥公司合作、進行臨床研究以及接近性北美生命科學供應鏈的優勢，不斷提升自身影響力。巴西擁有成熟的大學和生物醫學實驗室，在生物多樣性、感染疾病、腫瘤學和公共衛生研究領域擁有深厚的科學底蘊。英國在基因組學、結構生物學、轉化研究和早期生物技術領域依然保持著舉足輕重的地位，這得益於其強大的產學研合作基礎和豐富的健康數據資源。德國在藥物化學、工程、生物製劑、診斷技術和高品質的實驗室基礎設施方面實力雄厚，而法國則在免疫學、腫瘤學、神經科學、罕見疾病和公共研究網路方面擁有豐富的專業知識。俄羅斯在化學、病毒學、免疫學和疫苗相關研究方面具備科學研究實力，但國際合作趨勢和監管環境正在影響其參與程度。義大利和西班牙透過強大的醫學教育、腫瘤學研究、神經科學、感染疾病研究以及參與歐洲研究框架來支持藥物研發。中國在生物技術、藥物化學、基因組學、生物製藥和人工智慧驅動的研究領域正迅速發展，這得益於大規模的研發投入和日益增多的科學出版物。印度是化學服務、生物支持、資訊學、仿製學名藥相關專業知識以及日益一體化的藥物研發能力的重要中心，其大規模的科研人口為其發展奠定了堅實的基礎。日本在藥物研發、再生醫學、結構生物學和精準醫學領域保持著高水準，這得益於其嚴格的科學標準。澳洲在臨床應用、免疫學、腫瘤學、感染疾病研究以及強大的學術網路方面做出了貢獻。韓國在國家創新計畫和先進醫療基礎設施的支持下，在生物製藥、細胞療法、基因組學、數位醫療和轉化生物技術領域取得了進展。

為藥物研發服務產業的領導者提供的實用建議

產業領導者應優先考慮整合生物目標、藥物化學、轉化藥理學、計算科學和生物標記規劃的藥物發現模型，並從一開始就將其納入考慮。建立高品質、可互通的數據系統對於確保研究結果的可重複性、為人工智慧部署做好準備以及做出合理的決策至關重要。各機構應投資於疾病相關模型和人類生物學平台，以提高轉換可靠性，然後再將候選化合物推進到下一階段。人工智慧的部署應透過結合預測分析和實驗檢驗的檢驗封閉回路型工作流程來實現，而不是僅依賴演算法輸出。申辦方應根據科學深度、資料完整性、檢測可重複性、品質系統、智慧財產權保護、法規理解和跨職能溝通能力來評估服務合作夥伴。多元化的區域藥物發現網路可以提高獲得專業知識、疾病相關生物學知識和運作韌性的途徑，但這需要強力的管治和一致的品質標準。此外，領導者應加強早期安全性評估、ADME最佳化和生物標記策略，以降低下游流程的藥物流失率。最後，學術機構、公共機構、臨床網路和專業服務供應商之間的合作模式可以改善新標靶、患者衍生數據和新興治療技術的取得。

藥物發現服務分析的調查方法

本執行摘要採用系統性的二手調查方法撰寫，重點檢驗、公開可用且有資料支持的資訊來源。研究途徑包括對同行評審的生物醫學文獻、監管指南、公共衛生資料庫、專利和出版物趨勢、臨床研究註冊庫、政策文件、學術研究成果以及國際公認的生命科學相關報告的審查。研究結果透過交叉引用科學、監管、技術和區域證據進行檢驗，以識別藥物研發服務中不受市場規模、市場佔有率或預測影響的一致模式。此調查方法強調證據的品質、資訊來源的可靠性、與藥物研發工作流程的相關性以及跨區域和治療領域的一致性。特別關注標靶檢驗、轉化模型開發、人工智慧應用、檢測方法的可重複性、安全性評估、生物標記整合以及區域研發能力。本分析排除宣傳性聲明，避免對特定公司進行定位，而是著重關注產業層面的趨勢、科學促進因素以及對製藥、生物技術、學術和公共研究生態系統中決策者的實際影響。

結論：引領藥物發現服務的未來

藥物研發服務正發展成為推動科學創新、提升營運效率和促進轉化決策的策略引擎。整合外包、疾病相關生物學、精準醫療、自動化、人工智慧以及日益增強的區域專業化正在重塑這一行業。人工智慧雖然加速了假設生成和數據解讀，但經過實驗檢驗的科學仍然是可靠藥物研發的基礎。區域和國家層面的生態系統各具優勢，涵蓋了從先進的生物醫學基礎設施和監管專業知識到患者多樣性、計算科學和新興生物技術能力等各個方面。對於產業領導者而言，成功的關鍵在於選擇能夠提升數據品質、生物有效性、安全性洞察和跨學科整合的合作夥伴和營運模式。那些能夠將嚴謹的科學、數位應對力、合乎道德的管治以及全球合作相結合的機構，將更有能力推動更有前景的候選療法的研發，並在藥物研發的早期階段提高效率。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 藥物研發服務市場：依服務類型分類

  • 化學服務
    • 藥物化學
    • 合成化學
    • 胜肽合成
  • 生物服務
    • 基於細胞的檢測
    • 生化分析
    • 分子生物學
    • 微生物服務
  • 藥物代謝和藥物動力學
    • 體外ADME
    • 體內藥物動力學
    • 生物分析
  • 藥理學服務
  • 毒理學服務
    • 急性毒性
    • 慢性毒性
    • 基因毒性
  • DMPK 服務
    • 吸收試驗
    • 分佈研究
    • 代謝研究
  • 生物標誌服務

第8章 藥物發現服務市場：依技術分類

  • 計算生物學
    • 生物資訊學
    • 化學資訊學
    • 分子建模
  • 流式細胞技術
  • 高通量篩檢
    • 生化分析
    • 基於細胞的檢測
    • 無標定檢測
  • 質譜分析
  • 核磁共振
  • X光晶體結構分析

第9章 藥物發現服務市場：依藥物類型分類

  • 低分子化合物
  • 生物製劑
    • 單株抗體
    • 重組蛋白
    • 疫苗
    • 細胞療法
    • 基因治療

第10章 藥物研發服務市場：依服務交付模式分類

  • 內部服務
  • 外包服務

第11章 藥物研發服務市場：依治療領域分類

  • 心血管疾病
  • 神經病學
    • 神經退化性疾病
    • 精神疾病
  • 感染疾病
    • 病毒性疾病
    • 細菌感染疾病
  • 代謝性疾病
    • 糖尿病
    • 肥胖
  • 腫瘤學
  • 免疫學
    • 自體免疫疾病
    • 發炎性疾病
  • 呼吸系統疾病
  • 消化系統疾病

第12章 藥物發現服務市場：依最終用戶分類

  • 學術研究機構
  • 生技公司
  • 受託研究機構
  • 製藥公司
  • 政府機構

第13章 藥物研發服務市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章 藥物發現服務市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 藥物研發服務市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Alloy Therapeutics, Inc.
  • Aragen Life Sciences Private Limited
  • BioAscent Discovery Ltd
  • Charles River Laboratories, Inc.
  • Charnwood Discovery Limited
  • Crown Bioscience, Inc.
  • Curia Global, Inc.
  • Domainex Limited
  • Edelris SAS
  • Enamine Ltd.
  • Eurofins Scientific SE
  • Evotec SE
  • Medicilon Inc.
  • Metrion Biosciences Limited
  • Oncodesign Services SAS
  • Pelago Bioscience AB
  • Pharmaron Beijing Co., Ltd.
  • Proteros biostructures GmbH
  • Reaction Biology Corp.
  • Sai Life Sciences Limited
  • Selvita SA
  • SpiroChem AG
  • Sygnature Discovery Limited
  • Symeres BV
  • Syngene International Limited
  • TCG Lifesciences Private Limited
  • Viva Biotech Holdings
  • WuXi AppTec Co., Ltd.
  • X-Chem, Inc.
Product Code: MRR-6611A511167C

The Drug Discovery Services Market is projected to grow by USD 31.90 billion at a CAGR of 10.59% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.76 billion
Estimated Year [2026] USD 17.31 billion
Forecast Year [2032] USD 31.90 billion
CAGR (%) 10.59%

Drug discovery services are increasingly central to how pharmaceutical, biotechnology, academic, and public health organizations identify, validate, optimize, and advance new therapeutic candidates. These services span target identification, assay development, high-throughput screening, hit-to-lead optimization, medicinal chemistry, structural biology, in vitro and in vivo pharmacology, ADME, toxicology, biomarker discovery, and early translational research. Demand is being shaped by the need to reduce attrition, improve reproducibility, accelerate timelines, and access specialized capabilities across complex modalities such as biologics, peptides, oligonucleotides, cell and gene therapies, radiopharmaceuticals, and targeted protein degraders. Scientifically, the sector is supported by decades of evidence showing that early-stage failures are often driven by insufficient target validation, poor pharmacokinetics, toxicity signals, and weak translational relevance. As a result, sponsors are prioritizing integrated drug discovery services that combine biology, chemistry, computational modeling, disease-relevant assays, and quality-controlled data generation. The executive priority is no longer simply outsourcing discrete tasks; it is building resilient discovery ecosystems that improve decision-making, shorten experimental learning cycles, and support more confident progression from discovery to preclinical development.

Transformative Shifts in the Drug Discovery Services Landscape

The drug discovery services landscape is undergoing transformative shifts driven by scientific complexity, regulatory expectations, digitalization, and the globalization of R&D networks. One major shift is the movement from linear outsourcing to integrated discovery partnerships, where multidisciplinary teams align around therapeutic hypotheses, target biology, chemistry strategy, and translational endpoints. Another shift is the growing use of disease-relevant models, including patient-derived cells, organoids, advanced co-culture systems, and humanized models, to improve biological relevance before clinical testing. Precision medicine is also reshaping discovery workflows by linking genomics, proteomics, metabolomics, phenotypic data, and biomarker strategies to patient segmentation earlier in the process. At the same time, regulatory science is encouraging stronger evidence packages for safety, mechanism of action, data integrity, and model justification. The adoption of automation, laboratory information management systems, electronic notebooks, and standardized data pipelines is improving reproducibility and auditability. These shifts are creating a more evidence-led service environment in which speed matters, but decision quality, traceability, and translational validity are increasingly decisive.

Cumulative Impact of Artificial Intelligence on Drug Discovery Services

Artificial intelligence is having a cumulative impact across drug discovery services by improving how organizations search chemical and biological space, prioritize targets, design molecules, interpret omics data, and plan experiments. AI-enabled methods are being applied to target identification, protein structure prediction, virtual screening, de novo molecular design, synthetic route planning, image-based phenotypic screening, toxicity prediction, and patient stratification. Peer-reviewed advances in structural prediction and machine learning-based molecular modeling have demonstrated practical value in hypothesis generation, while laboratory validation remains essential because computational predictions can be limited by biased datasets, incomplete biology, and poor transferability across disease contexts. The most effective AI adoption is therefore not a replacement for experimental discovery but a closed-loop model in which algorithms propose, laboratories test, and resulting data refine subsequent predictions. For service providers and sponsors, the strategic value of AI lies in reducing unproductive experimentation, identifying non-obvious patterns, improving compound prioritization, and enabling more disciplined portfolio decisions. Data governance, model transparency, secure data sharing, and rigorous validation are becoming critical differentiators as AI becomes embedded in discovery operations.

Key Regional Insights Across Global Drug Discovery Services

Asia-Pacific is strengthening its role in drug discovery services through expanding biotechnology clusters, government-supported biomedical innovation, high scientific output, and cost-competitive research infrastructure across major economies. The region benefits from large patient populations, growing clinical and translational research capabilities, and increasing investment in genomics, biologics, and precision medicine. North America remains a leading hub for advanced discovery science, supported by mature pharmaceutical and biotechnology ecosystems, strong academic research, venture financing, advanced laboratory infrastructure, and established regulatory pathways that emphasize data quality and safety. Latin America is gaining relevance through biodiversity-driven research, improving clinical research capacity, and expanding academic-industry collaboration, particularly in infectious disease, oncology, and metabolic disorders. Europe continues to emphasize high-quality biomedical research, regulatory rigor, cross-border scientific collaboration, and public-private innovation frameworks, with notable strength in translational medicine, biologics, rare diseases, and advanced therapeutic modalities. The Middle East is investing in biomedical research capacity, genomics programs, specialized healthcare infrastructure, and innovation zones that support long-term diversification into life sciences. Africa is increasingly important for infectious disease research, genomic surveillance, population health studies, and locally relevant therapeutic innovation, supported by expanding research networks and international collaborations. Across these regions, drug discovery services are being shaped by the need for scientific specialization, ethical research practices, robust data infrastructure, and regionally relevant disease insights.

Key Group Insights Shaping Drug Discovery Services

ASEAN is emerging as a collaborative life sciences region, supported by expanding biomedical research capacity, improving regulatory coordination, and growing interest in infectious disease, metabolic disease, oncology, and tropical medicine research. GCC countries are prioritizing healthcare transformation, genomic medicine, biotechnology investment, and research infrastructure as part of broader economic diversification strategies, creating opportunities for discovery partnerships linked to precision health and regional disease burdens. The European Union provides a highly structured environment for drug discovery services through harmonized regulatory frameworks, multinational research programs, strong academic networks, and an emphasis on data protection, ethics, and translational science. BRICS countries contribute scale, scientific talent, manufacturing linkages, diverse disease populations, and increasing public and private investment in biotechnology, making the group relevant for both discovery and downstream development integration. G7 economies remain influential due to advanced research institutions, mature intellectual property frameworks, high regulatory standards, and concentration of specialized expertise in biologics, computational discovery, advanced analytics, and complex therapeutic modalities. NATO member countries, while not a life sciences bloc, include many economies with strong biomedical research systems, secure data infrastructure priorities, and defense-linked interest in medical countermeasures, biodefense, infectious disease preparedness, and resilient pharmaceutical supply chains. Together, these groups shape drug discovery services through policy alignment, research funding, cross-border collaboration, regulatory expectations, and the development of secure, innovation-oriented ecosystems.

Key Country Insights in Drug Discovery Services

The United States is a major center for drug discovery services due to its dense network of biotechnology firms, academic medical centers, advanced laboratories, venture funding, and regulatory experience across small molecules, biologics, and advanced therapies. Canada contributes strong capabilities in academic research, artificial intelligence, biologics, immunology, neuroscience, and translational medicine, supported by collaborative public research systems. Mexico is building relevance through pharmaceutical manufacturing links, clinical research activity, and proximity to North American life sciences supply chains. Brazil offers scientific depth in biodiversity, infectious disease, oncology, and public health research, supported by established universities and biomedical institutes. The United Kingdom remains influential in genomics, structural biology, translational research, and early-stage biotechnology, supported by strong academic-industry linkages and health data resources. Germany brings strengths in medicinal chemistry, engineering, biologics, diagnostics, and high-quality laboratory infrastructure, while France contributes expertise in immunology, oncology, neuroscience, rare diseases, and public research networks. Russia has scientific capabilities in chemistry, virology, immunology, and vaccine-related research, though international collaboration dynamics and regulatory conditions influence engagement. Italy and Spain support drug discovery through strong academic medicine, oncology research, neuroscience, infectious disease studies, and participation in European research frameworks. China has expanded rapidly in biotechnology, medicinal chemistry, genomics, biologics, and AI-enabled research, supported by large-scale R&D investment and growing scientific publication output. India is a significant destination for chemistry services, biology support, informatics, generics-linked expertise, and increasingly integrated discovery capabilities, strengthened by a large scientific workforce. Japan remains highly advanced in pharmaceutical research, regenerative medicine, structural biology, and precision medicine, supported by rigorous scientific standards. Australia contributes through clinical translation, immunology, oncology, infectious disease research, and strong academic networks. South Korea is advancing in biologics, cell therapy, genomics, digital health, and translational biotechnology, supported by national innovation programs and sophisticated healthcare infrastructure.

Actionable Recommendations for Drug Discovery Services Leaders

Industry leaders should prioritize integrated discovery models that combine target biology, medicinal chemistry, translational pharmacology, computational science, and biomarker planning from the earliest stages. Building high-quality, interoperable data systems is essential for reproducibility, AI readiness, and defensible decision-making. Organizations should invest in disease-relevant models and human biology platforms to improve translational confidence before advancing candidates. AI should be deployed through validated, closed-loop workflows that pair predictive analytics with experimental confirmation rather than relying on algorithmic output alone. Sponsors should evaluate service partners based on scientific depth, data integrity, assay reproducibility, quality systems, intellectual property safeguards, regulatory awareness, and cross-functional communication. Diversifying regional discovery networks can improve access to specialized talent, disease-relevant biology, and operational resilience, but it requires strong governance and harmonized quality standards. Leaders should also strengthen early safety assessment, ADME optimization, and biomarker strategies to reduce downstream attrition. Finally, collaborative models involving academia, public institutions, clinical networks, and specialized service providers can improve access to novel targets, patient-derived data, and emerging therapeutic technologies.

Research Methodology for Drug Discovery Services Analysis

This executive summary is developed using a structured secondary research methodology focused on verified, publicly available, and data-backed sources. The research approach includes review of peer-reviewed biomedical literature, regulatory guidance, public health databases, patent and publication trends, clinical research registries, policy documents, academic research outputs, and internationally recognized life sciences reports. Findings are triangulated across scientific, regulatory, technological, and regional evidence to identify consistent patterns in drug discovery services without relying on market sizing, market share, or forecasting. The methodology emphasizes evidence quality, source credibility, relevance to discovery workflows, and consistency across geographies and therapeutic areas. Particular attention is given to target validation, translational model development, AI applications, assay reproducibility, safety assessment, biomarker integration, and regional R&D capacity. The analysis excludes promotional claims and avoids company-specific positioning, focusing instead on industry-level dynamics, scientific drivers, and actionable implications for decision-makers across pharmaceutical, biotechnology, academic, and public research ecosystems.

Conclusion: Advancing the Future of Drug Discovery Services

Drug discovery services are evolving into a strategic engine for scientific innovation, operational efficiency, and translational decision-making. The industry is being reshaped by integrated outsourcing, disease-relevant biology, precision medicine, automation, artificial intelligence, and growing regional specialization. While AI is accelerating hypothesis generation and data interpretation, experimentally validated science remains the foundation of credible discovery. Regional and country-level ecosystems are contributing distinct strengths, from advanced biomedical infrastructure and regulatory expertise to patient diversity, computational science, and emerging biotechnology capacity. For industry leaders, success will depend on selecting partners and operating models that strengthen data quality, biological relevance, safety insight, and cross-disciplinary integration. Organizations that combine rigorous science with digital readiness, ethical governance, and global collaboration will be best positioned to advance stronger therapeutic candidates and improve the productivity of early-stage drug development.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug Discovery Services Market, by Service Type

  • 7.1. Introduction
  • 7.2. Chemistry Services
    • 7.2.1. Medicinal Chemistry
    • 7.2.2. Synthetic Chemistry
    • 7.2.3. Peptide Synthesis
  • 7.3. Biology Services
    • 7.3.1. Cell-based Assays
    • 7.3.2. Biochemical Assays
    • 7.3.3. Molecular Biology
    • 7.3.4. Microbiology Services
  • 7.4. Drug Metabolism & Pharmacokinetics
    • 7.4.1. In Vitro ADME
    • 7.4.2. In Vivo Pharmacokinetics
    • 7.4.3. Bioanalysis
  • 7.5. Pharmacology Services
  • 7.6. Toxicology Services
    • 7.6.1. Acute Toxicity
    • 7.6.2. Chronic Toxicity
    • 7.6.3. Genotoxicity
  • 7.7. DMPK Services
    • 7.7.1. Absorption Studies
    • 7.7.2. Distribution Studies
    • 7.7.3. Metabolism Studies
  • 7.8. Biomarker Services

8. Drug Discovery Services Market, by Technology

  • 8.1. Introduction
  • 8.2. Computational Biology
    • 8.2.1. Bioinformatics
    • 8.2.2. Cheminformatics
    • 8.2.3. Molecular Modeling
  • 8.3. Flow Cytometry
  • 8.4. High Throughput Screening
    • 8.4.1. Biochemical Assays
    • 8.4.2. Cell Based Assays
    • 8.4.3. Label Free Assays
  • 8.5. Mass Spectrometry
  • 8.6. Nuclear Magnetic Resonance
  • 8.7. X Ray Crystallography

9. Drug Discovery Services Market, by Drug Type

  • 9.1. Introduction
  • 9.2. Small Molecules
  • 9.3. Biologics
    • 9.3.1. Monoclonal Antibodies
    • 9.3.2. Recombinant Proteins
    • 9.3.3. Vaccines
    • 9.3.4. Cell Therapies
    • 9.3.5. Gene Therapies

10. Drug Discovery Services Market, by Service Delivery Model

  • 10.1. Introduction
  • 10.2. In-house Services
  • 10.3. Outsourced Services

11. Drug Discovery Services Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Cardiovascular Disorders
  • 11.3. Neurology
    • 11.3.1. Neurodegenerative Disorders
    • 11.3.2. Psychiatric Disorders
  • 11.4. Infectious Diseases
    • 11.4.1. Viral Diseases
    • 11.4.2. Bacterial Infections
  • 11.5. Metabolic Disorders
    • 11.5.1. Diabetes
    • 11.5.2. Obesity
  • 11.6. Oncology
  • 11.7. Immunology
    • 11.7.1. Autoimmune Diseases
    • 11.7.2. Inflammatory Disorders
  • 11.8. Respiratory Diseases
  • 11.9. Gastrointestinal Diseases

12. Drug Discovery Services Market, by End User

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Biotechnology Companies
  • 12.4. Contract Research Organizations
  • 12.5. Pharmaceutical Companies
  • 12.6. Government Organizations

13. Drug Discovery Services Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Drug Discovery Services Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Drug Discovery Services Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Alloy Therapeutics, Inc.
  • 17.2. Aragen Life Sciences Private Limited
  • 17.3. BioAscent Discovery Ltd
  • 17.4. Charles River Laboratories, Inc.
  • 17.5. Charnwood Discovery Limited
  • 17.6. Crown Bioscience, Inc.
  • 17.7. Curia Global, Inc.
  • 17.8. Domainex Limited
  • 17.9. Edelris SAS
  • 17.10. Enamine Ltd.
  • 17.11. Eurofins Scientific SE
  • 17.12. Evotec SE
  • 17.13. Medicilon Inc.
  • 17.14. Metrion Biosciences Limited
  • 17.15. Oncodesign Services S.A.S.
  • 17.16. Pelago Bioscience AB
  • 17.17. Pharmaron Beijing Co., Ltd.
  • 17.18. Proteros biostructures GmbH
  • 17.19. Reaction Biology Corp.
  • 17.20. Sai Life Sciences Limited
  • 17.21. Selvita S.A.
  • 17.22. SpiroChem AG
  • 17.23. Sygnature Discovery Limited
  • 17.24. Symeres B.V.
  • 17.25. Syngene International Limited
  • 17.26. TCG Lifesciences Private Limited
  • 17.27. Viva Biotech Holdings
  • 17.28. WuXi AppTec Co., Ltd.
  • 17.29. X-Chem, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY SERVICES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DRUG DISCOVERY SERVICES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DRUG DISCOVERY SERVICES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DRUG DISCOVERY SERVICES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL DRUG DISCOVERY SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL DRUG DISCOVERY SERVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMISTRY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMISTRY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMISTRY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MEDICINAL CHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MEDICINAL CHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MEDICINAL CHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SYNTHETIC CHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYNTHETIC CHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SYNTHETIC CHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL-BASED ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL-BASED ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL-BASED ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR BIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR BIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MOLECULAR BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MICROBIOLOGY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICROBIOLOGY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICROBIOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG METABOLISM & PHARMACOKINETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG METABOLISM & PHARMACOKINETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG METABOLISM & PHARMACOKINETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN VITRO ADME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN VITRO ADME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN VITRO ADME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN VIVO PHARMACOKINETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN VIVO PHARMACOKINETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN VIVO PHARMACOKINETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACOLOGY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACOLOGY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TOXICOLOGY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TOXICOLOGY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOXICOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE TOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE TOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE TOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC TOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC TOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC TOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOTOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENOTOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOTOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DMPK SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DMPK SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DMPK SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ABSORPTION STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ABSORPTION STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ABSORPTION STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DISTRIBUTION STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DISTRIBUTION STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DISTRIBUTION STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL METABOLISM STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL METABOLISM STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL METABOLISM STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOMARKER SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOMARKER SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOMARKER SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOINFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOINFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOINFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHEMINFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHEMINFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHEMINFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MOLECULAR MODELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MOLECULAR MODELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MOLECULAR MODELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL BASED ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELL BASED ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL BASED ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL LABEL FREE ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL LABEL FREE ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL LABEL FREE ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEAR MAGNETIC RESONANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEAR MAGNETIC RESONANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEAR MAGNETIC RESONANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL X RAY CRYSTALLOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL X RAY CRYSTALLOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL X RAY CRYSTALLOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IN-HOUSE SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IN-HOUSE SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL IN-HOUSE SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL OUTSOURCED SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL OUTSOURCED SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL OUTSOURCED SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VIRAL DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL VIRAL DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL VIRAL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL OBESITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL OBESITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL OBESITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFLAMMATORY DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL INFLAMMATORY DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFLAMMATORY DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL RESPIRATORY DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL RESPIRATORY DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL RESPIRATORY DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL GASTROINTESTINAL DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL GASTROINTESTINAL DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL GASTROINTESTINAL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GOVERNMENT ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GOVERNMENT ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GOVERNMENT ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMISTRY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG METABOLISM & PHARMACOKINETICS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY DMPK SERVICES, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMISTRY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG METABOLISM & PHARMACOKINETICS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY DMPK SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMISTRY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG METABOLISM & PHARMACOKINETICS, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY DMPK SERVICES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMISTRY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG METABOLISM & PHARMACOKINETICS, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY DMPK SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMISTRY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG METABOLISM & PHARMACOKINETICS, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY DMPK SERVICES, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMISTRY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG METABOLISM & PHARMACOKINETICS, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 306. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY DMPK SERVICES, 2018-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 310. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 312. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 314. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 316. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. MIDDLE EAST DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 320. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 321. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMISTRY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 323. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 324. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG METABOLISM & PHARMACOKINETICS, 2018-2032 (USD MILLION)
  • TABLE 325. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 326. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY DMPK SERVICES, 2018-2032 (USD MILLION)
  • TABLE 327. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 328. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 330. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 332. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 333. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 334. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 336. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 337. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 338. NATO DRUG DISCOVERY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 339. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 340. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY CHEMISTRY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 342. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 343. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG METABOLISM & PHARMACOKINETICS, 2018-2032 (USD MILLION)
  • TABLE 344. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY TOXICOLOGY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 345. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY DMPK SERVICES, 2018-2032 (USD MILLION)
  • TABLE 346. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 347. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY COMPUTATIONAL BIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 348. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2032 (USD MILLION)
  • TABLE 349. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 351. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY SERVICE DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 352. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 353. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 354. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 355. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 356. G7 DRUG DISCOVERY SERVICES MARKET SIZE, BY IM